NGL Fine-Chem Limited (NGLFINE.NS)
INR 1122.3
(-4.99%)
INR 1122.3
(-4.99%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 929.03 Million INR | 43.97% |
| 2022 | 645.29 Million INR | -12.45% |
| 2021 | 737.09 Million INR | 38.27% |
| 2020 | 533.07 Million INR | -2.47% |
| 2019 | 546.6 Million INR | 9.17% |
| 2018 | 500.67 Million INR | -12.54% |
| 2017 | 572.49 Million INR | 33.95% |
| 2016 | 427.38 Million INR | 28.37% |
| 2015 | 332.91 Million INR | -1.21% |
| 2014 | 337 Million INR | 7.66% |
| 2013 | 313.01 Million INR | 14.32% |
| 2012 | 273.8 Million INR | 36.33% |
| 2011 | 200.83 Million INR | 19.59% |
| 2010 | 167.93 Million INR | 43.35% |
| 2009 | 117.15 Million INR | 24.34% |
| 2008 | 94.22 Million INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | -2.62 Billion INR | -382.69% |
| 2023 Q4 | 929.03 Million INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 FY | 929.03 Million INR | 43.97% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 812.63 Million INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 645.29 Million INR | 0.0% |
| 2022 FY | 645.29 Million INR | -12.45% |
| 2022 Q2 | 672.27 Million INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q4 | 737.09 Million INR | 0.0% |
| 2021 Q2 | 806.62 Million INR | 0.0% |
| 2021 FY | 737.09 Million INR | 38.27% |
| 2020 Q2 | 691.74 Million INR | 0.0% |
| 2020 FY | 533.07 Million INR | -2.47% |
| 2020 Q4 | 533.07 Million INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2019 Q2 | 599.48 Million INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 FY | 546.6 Million INR | 9.17% |
| 2019 Q4 | 546.6 Million INR | 0.0% |
| 2018 FY | 500.67 Million INR | -12.54% |
| 2018 Q4 | 500.67 Million INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q2 | 567.82 Million INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2017 Q4 | 572.49 Million INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 FY | 572.49 Million INR | 33.95% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 439.8 Million INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 FY | 427.38 Million INR | 28.37% |
| 2016 Q4 | 427.38 Million INR | 0.0% |
| 2016 Q2 | 307.1 Million INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2015 Q2 | 330.29 Million INR | 0.0% |
| 2015 FY | 332.91 Million INR | -1.21% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q4 | 332.91 Million INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2014 FY | 337 Million INR | 7.66% |
| 2014 Q4 | 337 Million INR | 0.0% |
| 2014 Q2 | 355.83 Million INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 FY | 313.01 Million INR | 14.32% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q2 | 306.43 Million INR | 0.0% |
| 2013 Q4 | 313.01 Million INR | 0.0% |
| 2012 Q4 | 273.8 Million INR | 0.0% |
| 2012 FY | 273.8 Million INR | 36.33% |
| 2011 Q4 | 200.83 Million INR | 0.0% |
| 2011 FY | 200.83 Million INR | 19.59% |
| 2010 FY | 167.93 Million INR | 43.35% |
| 2009 FY | 117.15 Million INR | 24.34% |
| 2008 Q4 | 94.22 Million INR | 0.0% |
| 2008 FY | 94.22 Million INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Abbott India Limited | 14.94 Billion INR | 93.784% |
| Cipla Limited | 59.15 Billion INR | 98.429% |
| Gland Pharma Limited | 19.37 Billion INR | 95.205% |
| GlaxoSmithKline Pharmaceuticals Limited | 17.96 Billion INR | 94.828% |
| Kopran Limited | 2.52 Billion INR | 63.134% |
| Marksans Pharma Limited | 5.95 Billion INR | 84.387% |
| Pfizer Limited | 6.33 Billion INR | 85.329% |
| Sanofi India Limited | 6.99 Billion INR | 86.72% |
| SMS Pharmaceuticals Limited | 4.97 Billion INR | 81.336% |
| TTK Healthcare Limited | 1.99 Billion INR | 53.473% |